Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Twelves, Christopher J."'
Autor:
Hubbard, M.E., Jove, M., Loadman, Paul, Phillips, Roger M., Twelves, Christopher J., Smye, S.W.
Yes
The tumour vasculature and microenvironment is complex and heterogeneous, contributing to reduced delivery of cancer drugs to the tumour. We have developed an in silico model of drug transport in a tumour cord to explore the effect of differ
The tumour vasculature and microenvironment is complex and heterogeneous, contributing to reduced delivery of cancer drugs to the tumour. We have developed an in silico model of drug transport in a tumour cord to explore the effect of differ
Externí odkaz:
http://hdl.handle.net/10454/12057
Autor:
Groh, C.M., Hubbard, M.E., Jones, P.F., Loadman, Paul, Periasamy, Nagarajan, Sleeman, B.D., Smye, S.W., Twelves, Christopher J., Phillips, Roger M.
The ability to predict how far a drug will penetrate into the tumour microenvironment within its pharmacokinetic (PK) lifespan would provide valuable information about therapeutic response. As the PK profile is directly related to the route and sched
Externí odkaz:
http://hdl.handle.net/10454/10002
Autor:
Evans, C.J., Phillips, Roger M., Jones, P.F., Loadman, Paul, Sleeman, B.D., Twelves, Christopher J., Smye, S.W.
Inadequate drug delivery to tumours is now recognised as a key factor that limits the efficacy of anticancer drugs. Extravasation and penetration of therapeutic agents through avascular tissue are critically important processes if sufficient drug is
Externí odkaz:
http://hdl.handle.net/10454/4570
Autor:
Albertella, M.R., Loadman, Paul, Jones, P.H., Phillips, Roger M., Rampling, R., Burnet, N., Alcock, C., Anthoney, Alan, Vjaters, E., Dunk, C.R., Harris, P.A., Wong, A., Lalani, A.S., Twelves, Christopher J.
PURPOSE: AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N penetrates deeply within tumors and undergoes selective activation to form AQ4, a potent topoisomerase II inhibitor, in hypoxic regions o
Externí odkaz:
http://hdl.handle.net/10454/4535
Autor:
Puri, Rajiv, Palit, V., Loadman, Paul, Flannigan, G. Michael, Shah, T.K., Choudry, G.A., Basu, Saurajyoti, Double, John A., Lenaz, G., Chawla, S., Beer, M., Kalken, C.V., de Boer, R., Beijnen, J.H., Twelves, Christopher J., Phillips, Roger M.
The quinone based bioreductive drug apaziquone (EO9) failed to demonstrate efficacy in previous phase II studies following intravenous administration. We determined the dose of apaziquone that can be safely administered intravesically and explored it
Externí odkaz:
http://hdl.handle.net/10454/4150
Publikováno v:
Journal of Public Health, 2014 Mar 01. 36(1), 56-64.
Externí odkaz:
https://www.jstor.org/stable/45158646
Autor:
Rampling, Roy, Peoples, Sharon, Mulholland, Paul J., James, Allan, Al-Salihi, Omar, Twelves, Christopher J., McBain, Catherine, Jefferies, Sarah, Jackson, Alan, Stewart, Willie, Lindner, Juha, Kutscher, Sarah, Hilf, Norbert, McGuigan, Lesley, Peters, Jane, Hill, Karen, Schoor, Oliver, Singh-Jasuja, Harpreet, Halford, Sarah E., Ritchie, James W.A.
PURPOSE: To perform a two-cohort, phase 1 safety and immunogenicity study of IMA950 in addition to standard chemo-radiotherapy (CRT) and adjuvant temozolomide in patients with newly diagnosed glioblastoma (GBM). IMA950 is a novel GBM specific therape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::3dd3ecc72f609da76275c82bd53f0a5b
https://eprints.gla.ac.uk/122342/7/122342.pdf
https://eprints.gla.ac.uk/122342/7/122342.pdf
Autor:
Mackay, Helen J.1, Twelves, Christopher J.2 c.twelves@Bradford.ac.uk
Publikováno v:
Nature Reviews Cancer. Jul2007, Vol. 7 Issue 7, p554-562. 9p. 2 Diagrams, 2 Charts.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.